Last reviewed · How we verify
Argatroban plus dual antiplatelet — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Argatroban plus dual antiplatelet (Argatroban plus dual antiplatelet) — General Hospital of Shenyang Military Region.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Argatroban plus dual antiplatelet TARGET | Argatroban plus dual antiplatelet | General Hospital of Shenyang Military Region | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Argatroban plus dual antiplatelet CI watch — RSS
- Argatroban plus dual antiplatelet CI watch — Atom
- Argatroban plus dual antiplatelet CI watch — JSON
- Argatroban plus dual antiplatelet alone — RSS
Cite this brief
Drug Landscape (2026). Argatroban plus dual antiplatelet — Competitive Intelligence Brief. https://druglandscape.com/ci/argatroban-plus-dual-antiplatelet. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab